A federal appeals court has affirmed an earlier ruling by the Patient Trial and Appeal Board of the U.S. Patent and Trademark Office, invalidating 22 claims of a patent owned by United Therapeutics (NSDQ:UTHR).
The patent covered treprostinil, the active ingredient in both SteadyMed‘s (NSDQ:STDY) Trevyent and United Therapeutics’ Remodulin. The court’s ruling sent STDY shares up 8% today, trading at $3.40 apiece in mid-morning activity.
Get the full story at our sister site, Drug Delivery Business News.
The post Appeals court affirms ruling in United Therapeutics, SteadyMed patent spat appeared first on MassDevice.